Hôpital Riviera-Chablais, Vaud-Valais
Rennaz, Canton of Vaud, 1847, Switzerland
Location status: Recruiting
Location contact
Paul Garin, PharmD
CONTACT
Paul Garin, PharmD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06902779
The aim of this study is to evaluate the impact of an enhanced collaboration between a hospital pharmacist and a community pharmacist during hospital discharge. For patients taking multiple medications, hospitalization often involves numerous changes to their treatment regimen. For community pharmacies, discharge prescriptions are often complex, and they sometimes lack the information that pharmacists need to deliver the treatment as safely as possible. As a result, there is a risk of medication errors, and a risk for patients. We aim to evaluate the benefits of this collaboration for adult patients admitted to the internal medicine ward of a regional hospital who are taking seven or more drugs and are being discharged to home.
The main question it aims to answer is : Does the enhanced collaboration reduce the number of drug-related problems encountered by community pharmacists with discharge prescriptions ? Researchers will compare patients when a hospital pharmacist is involved during the discharge process and when he or she is not involved, which corresponds to normal care.
The hospital pharmacist will not perform the intervention directly on the patient, but only with the community pharmacy. Once they agree to participate in the study, patients will only have to go to their usual community pharmacy after discharge and accept that the hospital transmits medical information to their usual pharmacy.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Rennaz, Canton of Vaud, 1847, Switzerland
Location status: Recruiting
Paul Garin, PharmD
CONTACT
Paul Garin, PharmD
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 7 days after hospital discharge
Community pharmacists will assess the number of drug-related problems (DRP) on the discharge that they faced when preparing the discharge medication. They will have to use the PharmDISC system, which is a validated tool for referencing drug-related problems faced in the community which was adapted from the drug-related problems classification system of the Pharmaceutical Care Network Europe (PCNE). Community pharmacists will also document the intervention performed for each DRP, and the resolution (yes/no) of the DRP.
Time frame: 7 days after hospital discharge
Patients' satisfaction related to their visit at the pharmacy after hospital discharge will be assessed using a questionnaire. Patients will be contacted via email or telephone
Time frame: Through study completion, approximately 6 months
The satisfaction of community pharmacists with the service provided by the hospital pharmacist at patient discharge will be evaluated
Time frame: 30 days after hospital discharge
Number of participants with hospital emergency department visits and hospital readmission in the same hospital within 30 days of discharge
Contact information is provided by the study sponsor or research team.
Anne-Laure Blanc, PharmD, PhD
CONTACT
Paul Garin, PharmD
CONTACT
Pharmacie des Hopitaux de l'Est Lemanique
Other
Enhanced Collaboration Between Hospital and Community Pharmacists to Improve the Hospital Discharge Process
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06451692
Brain Diseases, Central Nervous System Diseases
Aabenraa, Southern Denmark, Denmark
View Trial DetailsNCT06159699
COVID-19, Coronaviridae Infections
Tomsk, Russia
View Trial DetailsNCT06956820
Polypharmacy
Aachen, Germany
View Trial DetailsNCT07022990
Polypharmacy
New York, United States
View Trial Details